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Introduction: Hand transplantation was first reported in 1964, and is 
currently one of the challenges that the 21st century poses to Medicine. 
Several related studies and advances have been achieved, thus allowing 
to explore new alternatives for patient management. Many reference 
centers have performed their own analyzes based on their experience, 
which has led to increase the viability of this type of transplant. 
Objective: This review seeks to provide an overview of hand 
transplantation and to propose a management algorithm.
Materials and methods: Several criteria must be met to select 
candidates, including clinical, paraclinical and psychosocial assessment 
performed by a multidisciplinary team. Immunosuppression seeks to 
avoid rejection, while immunosuppressants must have appropriate 
serum levels to reduce adverse effects. Classical and atypical acute 
rejection cases have been reported, where the skin is the main target 
tissue. Chronic rejection cases are related to the blood vessels that 
become affected. Monitoring is performed using several tests, 
considering skin biopsy as the gold standard. 
Results: Drug therapy complications derive from drug toxicity, 
which are manifested as metabolic disorders, development of 
opportunistic infections and neoplasms. Rehabilitation and social 
aspects, such as patient satisfaction, should be evaluated during 
recovery to ensure adherence to immunosuppressive therapy. 
In 2011, the international registry of hand and composite tissue 
transplantation reported 39 cases of upper limb transplantation with 
multiple results. All this proves that to achieve optimal and viable 
results, a multidisciplinary team must conduct proper follow-up, 
and that the patient should have a support and motivation network, 
and comply with pharmacological management.
Conclusion: Further research is expected to create strategies to develop 
tolerance and, thus, reduce management by immunosuppression.
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| Resumen |
Introducción. El trasplante de mano ha sido uno de los retos del siglo 
XXI, cuyo primer caso reportado ocurrió en 1964. En este campo se han 
hecho estudios y avances que permitieron explorar nuevas alternativas 
para el manejo del paciente con trasplante de mano, por lo que diversos 
centros de referencia han realizado análisis basados en sus experiencias, 
las cuales permitieron lograr la viabilidad de este tipo de trasplante.
Objetivo. Esta revisión busca dar una visión general sobre el 
trasplante de mano y proponer un algoritmo de manejo.
Materiales y métodos. La selección de candidatos requiere una serie 
de criterios, tales como evaluación clínica, paraclínica y psicosocial, 
desarrollados por un equipo multidisciplinario. La inmunosupresión 
busca evitar el rechazo y los inmunosupresores deben tener los niveles 
séricos apropiados para reducir sus efectos adversos. Se han reportado 
casos de rechazo agudo clásico y atípico, donde la piel es el principal 
tejido blanco, y rechazo crónico, en el cual se afectan los vasos 
sanguíneos. El seguimiento se realiza con varias pruebas, de modo 
que la de oro es la biopsia de piel. 
Resultados. Las complicaciones del tratamiento farmacológico derivan 
de la toxicidad de los medicamentos y se manifiestan como alteraciones 
metabólicas, infecciones oportunistas y neoplasias. La rehabilitación 
y los aspectos sociales, como el grado de satisfacción del paciente, 
deben ser evaluados durante la recuperación para asegurar adherencia 
al tratamiento. En 2011 el registro internacional de alotransplante 
compuesto de mano reportó 39 casos de trasplante de extremidades 
superiores con resultados variables; todo esto evidencia que para lograr 
un resultado óptimo y viable del trasplante debe realizarse seguimiento 
por un equipo multidisciplinario, red de apoyo del paciente y motivación 
del mismo, junto con el cumplimiento del manejo farmacológico.
Conclusión. Se espera que nuevas investigaciones puedan crear 
estrategias para desarrollar tolerancia y, de esta forma, reducir el 
manejo mediante inmunosupresión.
Palabras clave: Trasplante de mano; Inmunosupresión; Alotrasplante 
compuesto vascularizado; Rechazo de injerto; Infección (DeCS).
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Introduction
Hand transplantation is categorized as vascularized composite 
allotransplantation (VCA) (1), and is different from solid organ 
transplantation (SOT), whose histological composition homogeneity 
is greater, and functionality occurs since the moment the transplantation 
takes place. In the case of VCA, transplantation consists of tissues 
such as skin, bone, muscle, tendons, nerves and blood vessels (2) that 
generate greater antigenic heterogeneity.
Although the survival of the recipient does not depend on VCA, 
as in most SOT cases, both improve the quality of life of patients (3). 
Despite these differences, VCA was equated to SOT in France as per 
Act 800 of August 6, 2004 (4). Furthermore, the U.S. Department of 
Health and Human Services published its decision to recognize VCA as 
organs (5). This decision was based on the following criteria: a) vca is 
vascularized and requires surgical anastomosis after transplantation; b) it 
is composed of multiple tissues; c) it must be recovered from a donor as 
an anatomical unit; d) it is transplanted into a recipient as an anatomical 
unit; e) it requires minimal manipulation; f) its use is homologous; g) 
it is not combined with devices or other elements; h) it is susceptible 
to ischemia, and i) it is susceptible to rejection (5). Additionally, the 
changes proposed to the National Organ Transplant Act in the United 
States would facilitate the hand donation and transplantation process (6).
Several reports on limb and face transplantation showed that 
VAC is more akin to SOT than to tissue transplantation (7-9). By the 
same token, the organ and tissue transplantation line of Universidad 
Nacional de Colombia considers that VAC should be treated as a 
solid organ. This procedure requires health personnel trained in 
transplantation to standardize management, and to open new scenarios 
for the application of organ transplantation (10).
History of hand transplantation
In 1964, Gilbert (11), ten years after the first successful kidney 
transplantation (12), performed the first hand transplantation in 
Ecuador. The procedure consisted of a unilateral graft transplant, and 
immunosuppressive management with azathioprine and prednisone 
to achieve graft survival for three weeks only (13). Due to these 
unsuccessful results, research on this field was halted for about three 
decades. Then, in 1998, a second attempt was made in Lyon (14); this 
time, the graft was removed 29 months after transplantation due to 
rejection caused by lack of adherence to treatment. In any case, these 
results allowed a new period for hand transplantation in the 21st century. 
Today, several groups work on hand transplantation with good 
results. The most relevant are found in Poland (15), France (16), 
Innsbruck (17) and Louisville (18).
Materials and methods
Patient selection and contraindications
The Baltimore group proposes the following inclusion criteria 
for the selection of candidates: age between 18 and 69 years, no 
coexisting medical conditions that may affect the outcome of the 
transplant (immunomodulatory, surgical or functional conditions), 
no psychiatric pathologies, no history of neoplasms in the last 10 
years or HIV infection, and amputation for at least six months prior 
to the transplantation, with a good faith attempt to use prostheses 
and rehabilitation.
Moreover, for solid organ transplantation (SOT), additional 
criteria must be met (19,20). Inherited peripheral and inflammatory 
neuropathies, as well as neuropathies associated with systemic 
(diabetes, amyloidosis) and toxic diseases (metals and drugs) 
should be considered as relative contraindications for VAC, since 
transplantation requires post-transplant nerve regeneration, which 
could negatively affect the recovery of sensitivity or motor function 
in the hand (3,21).
In general, exclusion criteria to be considered include patients 
under 18 or over 69 years of age, and conditions that affect: a) 
the immunomodulatory protocol, such as chronic infections (HIV, 
hepatitis C), and preexisting immunological malignancies or 
deficiencies; b) surgical success and healing of coagulopathies, 
hematological diseases, vascular collagen disorders or connective 
tissue disorders; and c) functional results (healing of nerves or 
bones) in the presence of lipopolysaccharidosis, amyloidosis, 
metabolic diseases or bone genetic diseases. Other exclusion criteria 
are autoimmune inflammatory arthritis and extensive and severe 
osteoarthritis. In addition, patients may be excluded due to any other 
problem developed during the selection process (19,20). Similarly, 
the loss of the hand should be unilateral or bilateral and the level of 
amputation limited to the forearm. 
Thereafter, a panel of screening tests is performed, including 
hematologic tests such as complete and differential blood count, 
reticulocyte count, platelet count, PT (prothrombin time), PTT (partial 
thromboplastin time), INR (international normalized ratio), ABO (for 
blood type compatibility; blood type A, B or O), Rh factor, major 
histocompatibility complex (MHC) and panel reactive antibodies (PRA). 
Metabolic tests include serum electrolytes, renal function 
panel, creatinine, uroanalysis and liver function. Infectious tests 
involve cytomegalovirus detection, Epstein-Barr, herpes simplex, 
toxoplasmosis, varicella-zoster (IgG and IgM when indicated), 
HIV 1 and 2, hepatitis C, syphilis, hepatitis B and Mantoux skin 
test (TST). Cardiopulmonary tests involve electrocardiogram and 
echocardiogram or pulmonary function test with DL02.
Finally, radiology tests include abdomen ultrasound (to discard a 
tumor), hand and stump ultrasound, computerized axial tomography 
(CT), conventional angiography, functional magnetic resonance, 
paranasal sinus x-ray (to discard an infection or tumor), thoracic and 
simple bilateral hand x-ray, and wrist and forearm x-ray as indicated 
(19,20).
Diagnostic images (radiography, CT, NMR, among others) are 
important because they characterize the structural integrity of soft 
tissues and the bone of the receptor, which indicate how healthy a 
tissue is, and prevents anastomosis in a diseased or injured tissue. In 
addition, they describe structural damage (maceration of distal residual 
tissues, bone fragmentation, intra-articular fracture extension), either 
caused by amputation or by subsequent surgical procedures. This 
guides the surgical process, in the best possible way, where muscle 
mass and bone integrity need to be preserved. They also exclude any 
underlying disease that may compromise the function of the transplant 
or contraindicate life-long immunosuppression.
Angiography or angioresonance is used to identify the appropriate 
anastomotic vascular pedicle (radial or ulnar) for grafting. It is worth 
noting that ultrasound is useful for identifying signs of endothelial 
proliferation during postoperative surveillance, which would indicate 
graft rejection (22).
However, the assessment of coincident MHC is recommended, 
since the number of acute rejections seems to correlate with the 
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number of mismatched MHC, whose compatibility, according to 
one hypothesis, correlates with the development of antibodies in the 
donor. Therefore, this also influences the risk of developing graft 
vasculopathy in VAC (23,24).
Lastly, a multidisciplinary team should perform a complete clinical 
assessment of the candidates, including specialists (gastroenterologist, 
ophthalmologist, dentist, etc.) and psychological and social work 
support (19,20).
Immunology of the hand
Unlike solid organs (kidney, heart, liver, etc.), the hand is coated 
with skin, which has a very high antigenic load (25). In 2005, Tung 
et al. demonstrated that skin rejection is the first event in studies of 
limbs transplantation in mice (26), which coincides with findings 
in humans. The cellular components of the skin, associated with 
immune response, are keratinocytes, langerhans cells and dendritic 
cells. Keratinocytes produce proinflammatory cytokines that activate 
these cells in the dermis and epidermis, and chemokines that attract 
circulating lymphocytes into inflammatory foci and regulate the 
function of langerhans cells in the immune response (27). 
On the other hand, Sugita et al., when performing epidermal cell 
cultures, found that the expression of the major histocompatibility 
complex (MHC) class II in keratinocytes was promoted in this 
type of cells, while CD86 was expressed in langerhans cells. This 
finding allows identifying the role of keratinocytes in the appearance 
of antigens, through toll-like receptors, as well as their role in the 
regulation of the immune response (28). These results confirm that 
skin has the ability to trigger a large-scale immune response that can 
lead to skin rejection in hand allografts.
Immunosuppressive protocols
Induction therapy with both monoclonal (alemtuzumab/basiliximab) 
and polyclonal antibodies (ATG, that is, antithymocyte globulin) has 
been used since the Lyon transplant in 1998 based on the patient’s 
immunological risk, and is followed by maintenance management, 
combined with mycophenolate mofetil (MMF), tacrolimus and 
steroids (25). In many studies, skin cell components have been 
characterized while searching alternatives to induce tolerance such 
as chimerism by transplantation of hematopoietic cells, together with 
cytokines of peripheral blood mononuclear cells in animal models, or 
reduction of pharmacological immunosuppression. This has yielded 
varying results, either transitory chimerism or risk of generating 
graft-versus-host disease (29-31).
Similarly, the experience of the Polish group, with six patients 
transplanted until 2011, reported the following scheme as a 
management protocol:
a) Induction: basiliximab, tacrolimus 5mg oral, MMF 2g oral, 
and methylprednisolone 1g intravenously. 
b) Day 1: tacrolimus 5mg oral twice a day, MMF 1g oral twice 
a day, and methylprednisolone 500 mg intravenously.
c) Day 2: basiliximab intravenously, tacrolimus 5mg oral twice 
a day, and MMF 1g oral twice a day.
d) Days 3-7: tacrolimus (seru level 20 ng/mL), MMF 2g oral 
(daily), and methylprednisolone 500mg intravenously.
e) Maintenance: tacrolimus (peak level 10-15 ng/ml), 56 months 
after transplantation. Management was done with tacrolimus 
(peak level 10 ng/mL), steroids (5 mg / d), and MMF (2g/d) (15).
Until the report disclosed in 2011, the French group had performed 
five hand transplantations with ATG or alemtuzumab for the 
management of induction therapy, and tacrolimus, prednisone and 
MMF for maintenance (16). Despite the low number of patients, 
both protocols have shown favorable outcomes. Therefore, it is 
suggested that each center, according to its experience and the 
individual characteristics of each patient, creates its own protocols 
for immunosuppression (15-18,32-40).
Surgical procedure
As for the surgical procedure to implant the hand, bones, tendons, 
nerves and blood vessels of both the stump and the hand graft are 
identified. The order of the union is: fixation of the bones by means of 
plates and screws usually used in cases of arm fracture, anastomosis 
of arteries and veins, muscle and tendon repair, nerve repair, and 
skin closure. Cold ischemia time varies between 50 minutes and 12 
hours (mean: 6 hours, 12 minutes) and depends, to a great extent, 




Globally, 85% of all hand transplant recipients have experienced at 
least one episode of rejection unrelated to induction or maintenance 
therapy (25) within the first year of transplantation. This is why it is 
considered as one of the main complications.
Rejection is identified by visual inspection and confirmed by 
skin biopsy, as it is a highly immunogenic tissue (43-46). Classical 
acute rejection is observed as an erythematous (diffuse or focal) 
maculopapular eruption, accompanied or not by edema and vesicles. 
Other clinical signs are desquamation, ulceration or necrosis (47,48). 
In addition, manifestations of atypical acute rejection affect the palmar 
skin and nails, so the lesion appears as a desquamative rash associated 
with dry skin, red papules and palmar thickening or lichenification, 
nail dystrophy, deformation or nail loss (47). 
Treatment for acute rejection includes topical tacrolimus or 
clobetasol ointments, as well as systemic steroids and monoclonal 
antibodies as needed (49,50). The histopathological characterization 
of skin rejection is performed using the Banff classification (51,52). In 
the skin samples, an increase in the expression of adhesion molecules 
(Intercellular Adhesion Molecule 1 o ICAM-1, E-Selectin and 
P-Selectin) is evidenced in the vascular endothelium of the graft, 
which is associated with the severity of the rejection (25, 53). In 
addition, lymphocyte infiltrate is observed with predominance 
of T CD4+, CD8+, CD3+, and CD68+ lymphocytes, and Foxp3 
transcription factor expression, which is also correlated with the 
severity of rejection (53-57).
Chronic rejection
Little is known about the risk of chronic rejection in humans, whereas 
hindlimb animal models with rats have shown thickening of the intima 
and light occlusion of the graft arteries at a histological level (47,58). 
In this model, repetitive episodes of acute rejection were induced and 
histological changes of chronic rejection were achieved, including 
loss of hair follicles and epithelium, and adnexial muscle atrophy, 
with macrophage infiltration and fibrosis.
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Vascular alterations are late findings of rejection, suggesting that 
multiple episodes of acute rejection may lead to vasculopathy in the 
graft (47,59,60). Therefore, TH1 and TH2 have been proposed as 
immune activation pathways mediated by Helper TCD4+ T cells. 
The former is associated with acute rejection and is mediated by 
IFN-, TNF-α and IL-2 proinflammatory cytokines that increase 
immunogenicity in allografts. On the other hand, the TH2 pathway 
induces tolerance by means of IL-4,5,6 and IL-10  , which inhibit 
the production of IFN , and Th1 cells to suppress the production of 
IL-6 and TNF-α  from monocytes. Nowadays, it is suggested that 
the TH2 pathway favors the production of alloantibodies, cytokines, 
and growth factors that induce the proliferation of TCD8+, cells, 
natural killer (NK) cells, B cells, macrophages, smooth muscle and 
endothelial cells that favor chronic rejection (61-63).
Pharmacological immunosuppression
Complications secondary to the immunosuppressive protocol, which 
prevent hand allograft rejection, may appear including infection, post-
transplant diabetes, hypertension, nephrotoxicity, hyperlipidemia, 
leukopenia, cardiovascular disease, bilateral hip osteonecrosis, and 
increased risk of developing certain cancers (3).
Opportunistic infections
One of the most common is cytomegalovirus (CMV) infection, 
perhaps due to the high risk of latent virus transmission forms in 
leukocytes, epithelial cells and hematopoietic bone marrow stem cells 
found in the hand allograft (64). This may increase morbimortality in 
the recipient, as well as decreased graft survival and increased risk of 
acute rejection episodes (14,65-68). Negative CMV receptors may 
get infected through blood transfusions, community transmission and 
false CMV negatives in the donor. In addition, treatment with drugs 
such as Ganciclovir (GCV), Valganciclovir (ValGCV), Foscarnet 
and Cidofovir, alone or in combination, should be initiated, while 
monitoring is performed with polymerase chain reaction (PCR) for 
CMV (55). 
Bonatti et al. (56), of the Innsbruck group, reported that their three 
hand receptors received antiviral prophylaxis with Ganciclovir (GCV) 
or Valganciclovir (valGCV) and still developed an infection by CMV. 
Two of them developed a complicated infection that required anti-
CMV, hyperimmunoglobulin, cidofovir and foscarnet. In contrast, the 
third patient suffered from one type of non-invasive viremia by CMV. 
Furthermore, Ravindra et al. (69), of the Louisville group, reported 
that two of their three patients developed CMV infection; one of them 
went into remission with oral GCV, and the other was administered 
the same medication but intravenously, with complete remission.
Other infections reported in these patients were caused by human 
papilloma virus, herpes simplex, Staphylococcus aureus, Clostridium 
difficile, contagious molluscum, Pseudomonas sp., candida mycosis 
and Alternaria alternata (32,70,71). In general, it is necessary to 
contemplate the same considerations of solid organ transplantation, 
although there is no evidence regarding prophylaxis.
Neoplasms
Since hand transplantation patients have been monitored for less than 
10 years, many of the side effects of long-term immunosuppression are 
still unknown, considering that, in general, they are healthy patients. 
So, people undergoing solid organ transplantation are known 
to be at least three to five times more likely to develop neoplasms 
compared to the general population. The most frequent types of 
cancer are associated with virus and skin cancer (72,73), which is 
why it is essential to consider the risk of developing different types of 
neoplasms in patients with vascularized composite allograft (VCA), 
in particular hand transplantation. The risk of developing different 
types of neoplasms must also be considered. Landin et al. (74) 
reported basal cell carcinoma in a bilateral hand transplant recipient 
in 2006; the patient had received alemtuzumab and then combination 
therapy using tacrolimus, MMF and prednisone. 360 days after the 
transplantation, a nodular, rounded, pigmented and smooth lesion 
of 3 mm of diameter was found in the right nasal wing, which was 
removed without recurrence. 
Kaufman et al. (18) reported the detection of mantle cell lymphoma 
in the third patient, who underwent hand transplantation by the 
Louisville group, and received alemtuzumab as an inducer, while 
tacrolimus and MMF were administered for maintenance.
Psychological aspects
The psychosocial factors in hand transplantation patients affect 
graft function and survival (75,76). This can be identified in the 
second hand transplantation in the world, which was performed in 
Lyon in 1998. This surgical procedure was successful although the 
patient did not adhere to the immunosuppressive management, nor 
to physical therapy; therefore, the patient required amputation of 
the graft in 2001 (14). This was related to the motivation and ability 
to incorporate transplantation experience in patients, which may 
lead to non-compliance with the pharmacological or rehabilitation 
regimen (77,78). 
Some of the risk factors identified in psychological assessments in 
candidates for hand transplantation include social isolation, shame, 
decreased self-esteem, depressive coping style and poor quality of life 
(79). For this reason, it is important to conduct a detailed psychiatric 
interview in which transplantation is addressed, and to supplement 
it with psychological tests to assess body image adaptation and 
integrity, before and after the transplant (80-84). This is useful to 
perform the necessary therapeutic interventions, detect difficulties 
in the psychological integration process of the graft and, thus, obtain 
the best possible results in the long term.
Rehabilitation
Although part of the success of hand transplantation is attributed to 
surgical planning, it is not the only aspect to be taken into account 
to achieve a successful outcome (85). Rehabilitation programs are 
fundamental for the recovery of functionality in the transplanted hand, 
since a successful process requires patient commitment. It is also 
necessary to ensure that the patient will count on a team of experts 
that can provide guidance in terms of long-term recovery goals and 
expectations (86-91). 
Before transplantation, therapists collect data on motion range, 
strength, stump sensitivity, and history of prosthesis use. They also 
find out if the patient feels pain, which is recorded by analogous 
verbal scale (48). As for the team of hand therapists, they should be 
responsible for the planning of therapy sessions, patient education 
and familiarization with information from transplant centers (32), 
which allows them to know the main complications and possible 
management. In addition, it is recommended to initiate therapy one 
week after surgery. 
However, this therapy should be performed five days a week 
for an average of four hours a day for the first three months after 
transplantation (48), which requires commitment from the patient 
and the caregiver. Likewise, since the intensity in days and hours 
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varies among patients, they should be adjusted based on recovery 
in each case (90,91).
Research on the emotional aspects of these patients has focused 
on depression, anxiety, personality disorders and substance abuse, 
since they are the most frequent alterations, and are associated with 
functionality recovery expectations after the transplantation (92,93). 
With this is mind, the need to assess the degree of satisfaction and 
improvement of the quality of life of transplanted patients arises. 
These aspects are assessed through evaluation questionnaires that 
have not been standardized yet in all hand-transplantation programs 
(94-97). Such questionnaires include a) DASH (Disabilities of the 
Arm, Shoulder and Hand), which allows obtaining subjective and 
objective data from the patient, if a decrease of 15 points or more is 
found, a significant recovery in functionality is considered (98); b) 
Sollerman Hand Function Test, which incorporates tasks based on the 
patient’s work and takes into account the quality of the grip patterns 
and strength to perform them (99,100); and c) The Carroll Upper 
Extremity Function Test, which evaluates the functional recovery 
of the graft (101).
Finally, the role of the caregiver is fundamental during the first 
post-transplantation phase, since patients, especially those receiving 
bilateral hand transplants, depend on someone else for daily living 
activities for weeks or months after the surgery. This is exacerbated 
by the physical fatigue caused by rehabilitation, immunosuppressive 
drugs and the emotional challenges of the demanding general program 
(48). Therefore, throughout the process, the family must be included 
to be provided with the necessary tools to meet this challenge in the 
best possible way.
State of the art
Information on the experience of each transplant center in the world is 
compiled by the International Registry of Hand and Composite Tissue 
Transplantation  (IRHCTT), where reports are delivered voluntarily 
(non-mandatory). In total, 89 hand transplantations were performed 
between 1998 and 2010 (102). The last report was published in 2010 
and provides data on the follow-up of 49 hand transplantations in 33 
patients (18 bilateral and 17 unilateral). Follow-up was performed on 
31 patients for minimum one year; the age range was 19 to 54 years, 
with a mean age of 32 years. Regarding sex, 31 patients were males. 
Finally, in relation to the transplantation itself, wrist (46%), distal 
forearm (19%), middle forearm (17%), proximal forearm (14%) and 
elbow (4%) were the most common. 
As a result, 30 patients regained tactile and discriminative 
sensitivity. Motor recovery was initiated in the extrinsic muscles 
(gross motor), and then in the intrinsic muscles of the hand, for 9 
to 15 months, in most transplanted patients (32). This motor return 
depends on the anatomical level of the transplant (distal is better than 
proximal), and on the postoperative rehabilitation regimen; sensory 
feedback is conditioned to the regeneration of the nerve (47). Quality 
of life improved in 75% of patients, which enabled them to resume 
their work activities. Moreover, the systematic review by Landin 
et al. found that the score decreased by an average of 27.6±19.04 
points, through a disability comparison with the DASH survey, 
before and after the transplantation. Significant functional gains of 
the transplanted limb were also evidenced (103).
The main complications associated with transplantation are (32): 
a) opportunistic infections by CMV and herpes (29 cases); b) limited 
cutaneous necrosis (6 cases); c) permanent hyperglycemia (3 cases); 
d) arterial thrombosis (1 case); f) arteriovenous fistulae (1 case); g) 
end-stage kidney disease (1 case) that required hemodialysis 8 years 
after hand transplantation; h) transplant loss (1 case) due to poor 
adherence to treatment (29 months post-transplant), with conscious 
patient decision to suspend immunosuppression; i) intimal hyperplasia 
at day 245 post-transplant (1 case); j) bilateral transplantation 
involving bacterial infection (day 45 post-transplant), and k) bilateral 
hand and face transplantation, which resulted in death by cerebral 
anoxia (day 65 post-transplant).
However, IRHCTT does not take into account the cases reported by 
the Chinese groups, including Pei et al. (104), who reported 15 hand 
transplantations performed in 12 patients between 1999 and 2008, 
with a mean age of 34 years (19-52 years). Seven of these patients 
lost the grafts due to lack of adherence to the treatment. Overall, the 
results were poor, compared to transplantations performed in other 
centers around the world.
When comparing unilateral and bilateral transplantation with 
DASH scores, better functional results were observed in bilateral 
transplants. Even so, the results were positive for both groups from 
an overall perspective, which implies independence and return to the 
patients’ work activities (105,106).
Future of hand transplantation
Despite advances in immunosuppressive management and 
rehabilitation programs, there are still limitations, such as nerve 
regeneration of the transplanted hand, which occurs both at the distal 
and proximal levels. The case of proximal segment amputations is 
more relevant due to the difficulty of adapting to the prosthesis, 
which is why the transplant is required. Nevertheless, new research 
is expected to develop strategies to improve this aspect (3,107).
Immunosuppressive protocols are another important factor in 
hand transplantation, since there would be no graft survival without 
them. Currently, no protocols develop immunocompetence in the 
transplanted patient to avoid immunosuppression. Thus, these 
strategies are expected to be established in the future, to prevent the 
side effects of pharmacological immunosuppression. 
It should be noted that protocols that include transient or sustained 
chimerism have already been developed; however, in this case a living 
donor is needed, which is not possible in hand transplantation (108).
Today, research on autotransfusion protocols and mesenchymal 
stem cells that regulate the possible decline of the immune response 
can be found, even if its use is limited to experimental studies. 
Although the use of mesenchymal bone marrow cells has shown to 
generate stable chimerism and prolong transplant survival in animal 
models, it has not yet been tested in humans (109,110).
Another modality under study is based on the use of bioreactors 
to prolong ex vivo, that is, outside the donor and the recipient, in 
an alternate environment, to extend the survival of the graft and to 
modulate its immunogenicity so as to improve the function of the 
graft (111).
It has also been mentioned that patients undergoing hand 
transplantation have a history of difficulty to adapt to prostheses, 
despite their interest and the interventions made by specialists to 
achieve this goal. This entailed high rejection rates of these devices 
(112,113). The options offered to patients with amputations of upper 
limbs have changed and expanded in order to cover the physical 
demands of potential candidates. 
At present, advances have been made in prostheses adaptation and 
management, such as the case of selective muscular reinnervation 
in proximal amputation cases, which has allowed to develop the 
perception and position of the amputated segment. This technique 
consists of using non-functional muscles as amplifiers of the non-
functional nerves and, thus, extending the nerve cover as distal as 
possible, approaching the distal end of the prosthesis (115,116). 
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However, the main causes of prostheses abandonment include 
adaptation difficulties, lack of participation in the selection of the 
prosthesis, functionality, patient expectations and education on the 
proper use of the prosthesis. Thus, people who participate in the 
selection of devices are more successful in adherence to their everyday 
use. (117). 
In addition, there are six options in the market for the patients 
with upper limb amputation: not using a prosthesis, using passive 
prosthesis, body propulsion, electric propulsion, hybrid propulsion or 
specific activity propulsion. Choices must be made with the patient, 
so that proper assessment and advice can be provided for a correct 
selection (118). Because the devices do not fulfill all the activities 
of daily life, and to be able to respond to the demands of the users 
and their profession, it is necessary to use more than one device. To 
be successful and to meet patient expectations, their opinion on the 
process is essential (119,120). 
Finally, hand transplantation and prosthesis adaptation should not 
be seen as mutually exclusive, but as treatment options that differ 
from the risk and benefit profile for the patient, and from their ethical, 
clinical, aesthetic and functional implications (121).
Conclusions
Hand transplantation, rather than a composite tissue transplant, 
should be considered as an organ transplant that depends on the 
comprehensive management by a multidisciplinary team, which 
requires a support network and motivation from the patient, along 
with compliance with pharmacological management. 
When rejection occurs, it should be classified in order to determine 
the treatment. In consequence, a skin biopsy is considered as the gold 
standard for diagnosing acute rejection, although its role in chronic 
rejection should be questioned, since it can generate false negatives 
according to the depth of the sample. 
Also, rehabilitation is a vital process to recover the functionality 
of the hand, as well as psychological accompaniment to prevent graft 
loss due to lack of adherence to the treatment. 
Finally, new research is expected to create strategies to develop 
tolerance and thereby reduce management through immunosuppression. 
In addition, the pros and cons of hand transplantation, the experience 
of the transplant group, the side effects of short- and long-term drugs, 
and the possible complications associated with immunosuppression 
in each of the hand VAC cases should always be evaluated.
To see the management algorithm, please refer to Annex 1.
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* Increase dosage of Tacrolimus
and oral steroids
* Resistance to steroids:
Basiliximab and Alemtuzumab
*Topical: Tacrolimus, corticoids
Improvement?
Treatment:
* Intensify
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immunosuppression
*Tacrolimus and/or
Alentuzumab
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CMV
Treatment:
*Ganciclovir
*Foscarnet
*Cidofovir
*Valganciclovir
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immunosuppression
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